NCT05491317View on ClinicalTrials.gov

A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors

PHASE1/PHASE2TerminatedINTERVENTIONAL

Enrollment

13

Participants

Timeline

Start Date

March 8, 2023

Primary Completion Date

August 11, 2025

Study Completion Date

August 11, 2025

Conditions

Non-CNS Tumor

Interventions

BIOLOGICAL

GEN1042

Intravenous

DRUG

Pembrolizumab

Intravenous

RADIATION

Radiotherapy

Radiotherapy

Trial Locations (3)

33076

Institut Bergonie, Bordeaux

69008

Centre Leon Berard, Lyon

94805

Institut Gustave Roussy, Villejuif

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors

collaborator

BioNTech SE

INDUSTRY

lead

Genmab

INDUSTRY